7CHB
Crystal structure of the SARS-CoV-2 RBD in complex with BD-236 Fab
Summary for 7CHB
Entry DOI | 10.2210/pdb7chb/pdb |
Descriptor | BD-236 Fab heavy chain, BD-236 Fab light chain, Spike protein S1, ... (5 entities in total) |
Functional Keywords | sars-cov-2, rbd, mab, antiviral protein, antiviral protein-immune system complex, antiviral protein/immune system |
Biological source | Homo sapiens More |
Total number of polymer chains | 3 |
Total formula weight | 71980.52 |
Authors | |
Primary citation | Du, S.,Cao, Y.,Zhu, Q.,Yu, P.,Qi, F.,Wang, G.,Du, X.,Bao, L.,Deng, W.,Zhu, H.,Liu, J.,Nie, J.,Zheng, Y.,Liang, H.,Liu, R.,Gong, S.,Xu, H.,Yisimayi, A.,Lv, Q.,Wang, B.,He, R.,Han, Y.,Zhao, W.,Bai, Y.,Qu, Y.,Gao, X.,Ji, C.,Wang, Q.,Gao, N.,Huang, W.,Wang, Y.,Xie, X.S.,Su, X.D.,Xiao, J.,Qin, C. Structurally Resolved SARS-CoV-2 Antibody Shows High Efficacy in Severely Infected Hamsters and Provides a Potent Cocktail Pairing Strategy. Cell, 183:1013-1023.e13, 2020 Cited by PubMed Abstract: Understanding how potent neutralizing antibodies (NAbs) inhibit SARS-CoV-2 is critical for effective therapeutic development. We previously described BD-368-2, a SARS-CoV-2 NAb with high potency; however, its neutralization mechanism is largely unknown. Here, we report the 3.5-Å cryo-EM structure of BD-368-2/trimeric-spike complex, revealing that BD-368-2 fully blocks ACE2 recognition by occupying all three receptor-binding domains (RBDs) simultaneously, regardless of their "up" or "down" conformations. Also, BD-368-2 treats infected adult hamsters at low dosages and at various administering windows, in contrast to placebo hamsters that manifested severe interstitial pneumonia. Moreover, BD-368-2's epitope completely avoids the common binding site of VH3-53/VH3-66 recurrent NAbs, evidenced by tripartite co-crystal structures with RBDs. Pairing BD-368-2 with a potent recurrent NAb neutralizes SARS-CoV-2 pseudovirus at pM level and rescues mutation-induced neutralization escapes. Together, our results rationalized a new RBD epitope that leads to high neutralization potency and demonstrated BD-368-2's therapeutic potential in treating COVID-19. PubMed: 32970990DOI: 10.1016/j.cell.2020.09.035 PDB entries with the same primary citation |
Experimental method | X-RAY DIFFRACTION (2.4 Å) |
Structure validation
Download full validation report
